First-of-Its-Kind Mobile Testing Platform Launched to Manage and Track On-Site COVID-19 Testing
By LabMedica International staff writers Posted on 28 Aug 2020 |
Image: Fionet’s workflow (Photo courtesy of Fio Corporation)
A new first-of-its-kind COVID-19 mobile testing and tracking platform aims to enable lab-grade diagnostic testing in clinics, pharmacies, workplaces, airports, nursing homes and other community-based locations.
The new COVID-19 testing, data collection and reporting solution, Fionet, has been developed jointly by Relay Medical Corp. (Toronto, Canada) and Fio Corporation (Toronto, Canada). The Fionet mobile testing and tracking platform has been specifically developed for controlled, rapid response to pandemics. The platform combines handheld devices linked to online AI-powered cloud, automating frontline testing and capturing test results for tracking. Fionet’s rugged, mobile devices are compatible with multiple third-party antigen and antibody COVID-19 rapid diagnostic tests (RDTs), which creates sourcing flexibility for RDTs that are of limited supply and continuously evolving. Fionet also connects with molecular testing devices such as PCRs.
Flexible and customizable, Fionet enables testing to be expanded beyond the few overburdened medical centers to small clinics, pharmacies, workplaces, airports, nursing homes, schools, etc. and performed at hospital-grade accuracy, in higher volume, faster-speed, and by less-skilled frontline workers. Fionet has a proven, positive impact on one million patients with infectious diseases in over a dozen countries and four continents.
“Community-based testing and real-time tracking is indispensable for combating pandemics like COVID-19. Fionet has already made this happen in the most challenging epidemic regions on the planet and we are now preparing for imminent deployment of our platform with several partners to combat COVID-19 at home and abroad,” said Dr Michael Greenberg, CEO of Fionet Rapid Response Group, a joint venture set up by Relay Medical and Fio Corp.
“The many transformational benefits delivered by Fionet have been validated and documented in several dozen scientific and medical journals. Fionet has successfully reduced testing errors by 23%, achieves 99.5%1 diagnostic accuracy rate compared to expert lab techs, and provides significant economic efficiencies,” said Yoav Raiter, CEO, Relay Medical Corp.
Related Links:
Relay Medical Corp.
Fio Corporation
The new COVID-19 testing, data collection and reporting solution, Fionet, has been developed jointly by Relay Medical Corp. (Toronto, Canada) and Fio Corporation (Toronto, Canada). The Fionet mobile testing and tracking platform has been specifically developed for controlled, rapid response to pandemics. The platform combines handheld devices linked to online AI-powered cloud, automating frontline testing and capturing test results for tracking. Fionet’s rugged, mobile devices are compatible with multiple third-party antigen and antibody COVID-19 rapid diagnostic tests (RDTs), which creates sourcing flexibility for RDTs that are of limited supply and continuously evolving. Fionet also connects with molecular testing devices such as PCRs.
Flexible and customizable, Fionet enables testing to be expanded beyond the few overburdened medical centers to small clinics, pharmacies, workplaces, airports, nursing homes, schools, etc. and performed at hospital-grade accuracy, in higher volume, faster-speed, and by less-skilled frontline workers. Fionet has a proven, positive impact on one million patients with infectious diseases in over a dozen countries and four continents.
“Community-based testing and real-time tracking is indispensable for combating pandemics like COVID-19. Fionet has already made this happen in the most challenging epidemic regions on the planet and we are now preparing for imminent deployment of our platform with several partners to combat COVID-19 at home and abroad,” said Dr Michael Greenberg, CEO of Fionet Rapid Response Group, a joint venture set up by Relay Medical and Fio Corp.
“The many transformational benefits delivered by Fionet have been validated and documented in several dozen scientific and medical journals. Fionet has successfully reduced testing errors by 23%, achieves 99.5%1 diagnostic accuracy rate compared to expert lab techs, and provides significant economic efficiencies,” said Yoav Raiter, CEO, Relay Medical Corp.
Related Links:
Relay Medical Corp.
Fio Corporation
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants